Central diabetes insipidus revealing a hypophysitis induced by SARS-CoV-2 vaccine - 23/07/23
Doi : 10.1016/j.therap.2022.09.007
Taieb Ach a, b, ⁎ 
, Fatma Kammoun c, Hamza El Fekih a, b, Nassim Ben Haj Slama a, b, Siwar Kahloun b, d, Fatma Ben Fredj b, c, Chédia Laouani b, c, Koussay Ach a, b
, Fatma Kammoun c, Hamza El Fekih a, b, Nassim Ben Haj Slama a, b, Siwar Kahloun b, d, Fatma Ben Fredj b, c, Chédia Laouani b, c, Koussay Ach a, b a Department of Endocrinology, University Hospital of Farhat-Hached Sousse, 4000 Sousse, Tunisia
b Faculty of Medicine of Sousse, University of Sousse, 4000 Sousse, Tunisia
c Department of internal medicine, University Hospital of Sahloul Sousse, 4000 Sousse, Tunisia
d Department of infectious disease, University Hospital of Sahloul Sousse, 4000 Sousse, Tunisia
⁎Corresponding author.
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.
Articolo gratuito.
Si connetta per beneficiarne
Keywords : Hypophysitis, COVID-19, Endocrinopathy, Adjuvants vaccines, ASIA syndrome.
Il testo completo di questo articolo è disponibile in PDF.
Mappa
| ☆ | This report was notified in August 2022 to the Ethical board of the University Hospital of Farhat Hached of Sousse (Tunisia) and registered with the file number 60/2022. |
© 2022
Société française de pharmacologie et de thérapeutique. Pubblicato da Elsevier Masson SAS. Tutti i diritti riservati.
Vol 78 - N° 4
P. 453-455 - Luglio 2023 Ritorno al numero
Articolo precedente
- Atypical neurological toxicity attributed to oxaliplatin
- Wiem Daly, Ghozlane Lakhoua, Ahmed Zaiem, Ons Charfi, Sarrah Kastalli, Riadh Daghfous, Sihem El Aidli
- Central diabetes insipidus, hypophysitis and SARS-CoV-2 vaccine: Correspondence
- Rujittika Mungmunpuntipantip, Viroj Wiwanitkit
Benvenuto su EM|consulte, il riferimento dei professionisti della salute.